About Company
Milestones
with tiny microorganisms,
is evolving into the development
of therapeutics that transform
human lives
2023 – Present
Designated as an Excellent Corporate Research Center by the Ministry of Science and ICT (MSIT)
Received IND approval for Phase 2a clinical trial of LT-001 (MFDS)
Won the Minister’s Award for Bio Innovation Growth Company (Ministry of Trade, Industry and Resources)
Won the NutraIngredients-Asia Awards for HAC01
Expanded and relocated to new headquarters
Won the Patent Technology Award for HAC01 (MOIP, Ministry of Intellectual Property)
Completed Phase 1 clinical trial in Australia for LT-001, a therapeutic candidate for bacterial vaginosis
– Dr. my all “HYULDANG-N probiotics”
– Yuhan “DANG-Q-RAC”
2022 - 2016
Incorporated as a subsidiary of Yuhan
HAC-01, 1st-in-Korea approval for blood sugar-lowering functional probiotic (MFDS)
Secured KRW 4.4 billion Bridge Investment
Obtained IP Management Enterprise Certification (MOIP)
Secured KRW 8.0 billion Series A Investment
Incorporated as a subsidiary of TONYMOLY
Designated as a Family Company of Korea Research Institute of Bioscience and Biotechnology (KRIBB)
2015 - 2010
Commendation as a Leading New Growth Company from Daejeon Metropolitan City
Certified as an Inno-Biz Company (Technology Innovation SME)
Company name changed to ATOGEN Co., Ltd.
Certified as a Venture Company
Obtained ISO 9001 Certification
Established Corporate Research Institute
Ms. Jihee Kang appointed as Chief Executive Officer
Company Established